1251908-00-5

Basic information

• Product Name: 1-[(3S,4S)-1-benzyl-4-methylpiperidin-3-yl]-1,6-dihydrodipyrrolo[2,3-b:2',3'-d]pyridine
• Synonyms: 1-[(3S,4S)-1-benzyl-4-methylpiperidin-3-yl]-1,6-dihydrodipyrrolo[2,3-b:2',3'-d]pyridine
• CAS NO: 1251908-00-5
• Molecular Weight: 344.459
• Mol File: 1251908-00-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-[(3S,4S)-1-benzyl-4-methylpiperidin-3-yl]-1,6-dihydrodipyrrolo[2,3-b:2',3'-d]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(3S,4S)-1-benzyl-4-methylpiperidin-3-yl]-1,6-dihydrodipyrrolo[2,3-b:2',3'-d]pyridine(1251908-00-5)
• EPA Substance Registry System: 1-[(3S,4S)-1-benzyl-4-methylpiperidin-3-yl]-1,6-dihydrodipyrrolo[2,3-b:2',3'-d]pyridine(1251908-00-5)

Safety Data

• Hazardous Substances Data: 1251908-00-5(Hazardous Substances Data)

Upstream product

• 920966-02-5 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile 

Relevant articles and documents

Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors

Janus kinases (JAKs) play a crucial role in cytokine mediated signal transduction. JAK inhibitors have emerged as effective immunomodulative agents for the prevention of transplant rejection. We previously reported that the tricyclic imidazo-pyrrolopyridinone 2 is a potent JAK inhibitor; however, it had poor oral absorption due to low membrane permeability. Here, we report the structural modification of compound 2 into the tricyclic dipyrrolopyridine 18a focusing on reduction of polar surface area (PSA), which exhibits potent in vitro activity, improved membrane permeability and good oral bioavailability. Compound 18a showed efficacy in rat heterotopic cardiac transplants model.

FUSED PYRROLOPYRIDINE DERIVATIVE

[Problem] The present invention provides a condensed pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases caused by undesirable cytokine signal transduction or diseases caused by abnormal cytokine signal transduction. [Means for Solution] The present inventors have extensively studied a compound having a JAK inhibitory action, and as a result, they have found that a condensed pyrrolopyridine derivative which is the compound of the present invention has an excellent JAK inhibitory action, and is therefore useful as an agent for preventing or treating diseases caused by undesirable cytokine signal transduction or diseases caused by abnormal cytokine signal transduction, thereby completing the present invention.